<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zimbalist AS</submitter><funding>American Institute for Cancer Research</funding><funding>NCI NIH HHS</funding><funding>National Cancer Institute, United States</funding><pagination>1361</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9801571</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>22(1)</volume><pubmed_abstract>Research on the impact of metabolic abnormalities on breast cancer prognosis is limited by small samples and assessment of laboratory values at a single time point, often prior to cancer diagnosis and treatment. In this population-based cohort, time-updated laboratory values were adjusted for cancer treatment to assess the association between metabolic risk factors (glucose, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides) and breast cancer survival. 13,434 women diagnosed with stage I-III breast cancer from 2005-15 at Kaiser Permanente were included. All outpatient fasting glucose, HDL-C, LDL-C, and triglyceride values from diagnosis through 2019 or death were extracted from electronic medical records. Risk of breast cancer-specific</pubmed_abstract><journal>BMC cancer</journal><pubmed_title>Metabolic abnormalities and survival among patients with non-metastatic breast cancer.</pubmed_title><pmcid>PMC9801571</pmcid><funding_grant_id>632996</funding_grant_id><funding_grant_id>R01 CA251589</funding_grant_id><funding_grant_id>R01CA251589</funding_grant_id><pubmed_authors>Dillon DAR</pubmed_authors><pubmed_authors>Zimbalist AS</pubmed_authors><pubmed_authors>Mittendorf EA</pubmed_authors><pubmed_authors>Quesenberry C</pubmed_authors><pubmed_authors>Cespedes Feliciano EM</pubmed_authors><pubmed_authors>Caan BJ</pubmed_authors><pubmed_authors>Chen WY</pubmed_authors></additional><is_claimable>false</is_claimable><name>Metabolic abnormalities and survival among patients with non-metastatic breast cancer.</name><description>Research on the impact of metabolic abnormalities on breast cancer prognosis is limited by small samples and assessment of laboratory values at a single time point, often prior to cancer diagnosis and treatment. In this population-based cohort, time-updated laboratory values were adjusted for cancer treatment to assess the association between metabolic risk factors (glucose, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides) and breast cancer survival. 13,434 women diagnosed with stage I-III breast cancer from 2005-15 at Kaiser Permanente were included. All outpatient fasting glucose, HDL-C, LDL-C, and triglyceride values from diagnosis through 2019 or death were extracted from electronic medical records. Risk of breast cancer-specific</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2025-05-29T16:21:57.776Z</modification><creation>2025-04-19T18:09:34.067Z</creation></dates><accession>S-EPMC9801571</accession><cross_references><pubmed>36581817</pubmed><doi>10.1186/s12885-022-10430-9</doi></cross_references></HashMap>